Choices in Antipsychotic Therapy in Schizophrenia

References

• Swazey JP. Chlorpromazine in psychiatry: a study of therapeutic innovation. MIT Press, Cambridge, Massachusetts 1974
   Google Scholar
• Delay J, Deniker P, Harl JM. Utilisation en thérapeutique psychiatrique d'une phénothiazine d'action centrale élective. Ann Med Psychol 1952; 110: 112–31
   PubMedGoogle Scholar
• Bower WH. Chlorpromazine in psychiatric illness. N Engl J Med 1954; 251: 689–92
   Google Scholar
• Ayd FJ. The early history of modern psyehopharmacology. Neuropsychopharmacology 1991; 5: 71–84
   PubMed Web of Science ®Google Scholar
• Lehmann HE, Ban TA. The history of the psyehopharmacology of schizophrenia. Can J Psychiatry 1997; 42: 152–62
   PubMed Web of Science ®Google Scholar
• Casey JF, Bennett IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia: a controlled study of the relative effectiveness of, chlorpromazinepromazine, phenobarbital, and placebo. Arch Gen Psychiatry 1960; 2: 210–20
   PubMed Web of Science ®Google Scholar
• The National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia: effectiveness. Arch Gen Psychiatry 1964; 10: 246–61
   PubMed Web of Science ®Google Scholar
• Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325–51
   PubMed Web of Science ®Google Scholar
• Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151: 1409–16
   PubMed Web of Science ®Google Scholar
• Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426–33
   PubMed Web of Science ®Google Scholar
• Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47: 741–73
   PubMed Web of Science ®Google Scholar
• Schooler NR, Keith SJ. The clinical research base for the treatment of schizophrenia. Psychopharmacol Bull 1993; 29: 431–46
   PubMedGoogle Scholar
• Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79–91
   PubMed Web of Science ®Google Scholar
• Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1–10
   PubMed Web of Science ®Google Scholar
• Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47: 754–8
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992; 18: 515–42
   PubMed Web of Science ®Google Scholar
• Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996; 57: 35–40, suppl 9
   PubMed Web of Science ®Google Scholar
• Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987; 48: 13–9, suppl
   PubMed Web of Science ®Google Scholar
• Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47–53, suppl
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77: 185–202
   PubMed Web of Science ®Google Scholar
• Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987; 75: 74–7
   PubMed Web of Science ®Google Scholar
• Bitton RN, Schneider B. Endocrine, metabolic, and nutritional effects of psychotropic drugs. Adverse effects of psychotropic drugs, JM Kane, JA Lieberman. Guilford, New York 1992; 341–55
   Google Scholar
• Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986; 104: 777–82
   PubMed Web of Science ®Google Scholar
• Stille G, Fischer-Cornellsen K. Die Entwicklung von Clozapin (Leponex)—ein Mysterium?. Pharmakopsychiatrie im Wandel der Zeit: Erlebnisse und Ergebnisse; Wissenschaftsanekdotisches von Forschern und ihren Formeln, OK Linde. Khngenmunster, TiliaTilia 1988; 333–48
   Google Scholar
• Gross VH, Langner E. Das Wirkungsprofil eines chemisch neuartigen Brietbandneuroleptikums der Dibenzodiazepingruppe. Wien Med Wochenschr 1966; 40: 814–6
   Google Scholar
• Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I. Clozapine and agranulocytosis [Letter]. Lancet 1975; 2: 611
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96
   PubMed Web of Science ®Google Scholar
• Honigfeld G. Effects of the Clozapine National Registry System on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52–6
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996; 168: 23–31, suppl 29
   Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psyehopharmacology. US Department of Health, Education, and Welfare, Rockville, Maryland 1976
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40
   PubMed Web of Science ®Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538–46
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a, double-blind, fixed dose olanzapine, trial. Psychopharmacology 1996; 124: 159–67
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–23
   PubMed Web of Science ®Google Scholar
• Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998; 155: 914–20
   PubMed Web of Science ®Google Scholar
• Hirsch SR, Link CGG, Goldstein JM, Arvanitis LA. ICI, 204, 636:a new atypical antipsychotic, drug. Br J, Psychiatry 1996; 168: 45–56, suppl 29
   Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549–57
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46
   PubMed Web of Science ®Google Scholar
• Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58: 55–62, suppl 10
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152: 827–32
   PubMed Web of Science ®Google Scholar
• Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20–6
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a, double-blind, placebo- and haloperidol-controlled clinical trial with, olanzapine. Am J Psychiatry 1997; 154: 466–74
   PubMed Web of Science ®Google Scholar
• Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. J Clin Pharmacol Ther 1993; 54: 257–68
   Google Scholar
• Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155: 1113–6
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Hegarty JD. Cost considerations in the treatment of schizophrenia. CNS Drugs 1996; 5: 75–82
   Web of Science ®Google Scholar
• Knapp M. Costs of schizophrenia. Br J Psychiatry 1997; 171: 509–18
   PubMed Web of Science ®Google Scholar
• Rice DP, Kelman S, Miller LS. The economic burden of mental illness. Hosp Community Psychiatry 1992; 43: 1227–32
   PubMedGoogle Scholar
• Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4
   PubMedGoogle Scholar
• Frankenburg FR, Zanarini MC, Cole JO, McElroy SL. Hospitalization rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 1992; 4: 247–50
   Google Scholar
• Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630–8
   PubMed Web of Science ®Google Scholar
• Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26
   PubMed Web of Science ®Google Scholar
• Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41: 369–71
   PubMed Web of Science ®Google Scholar
• Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 1996; 40: 1132–4
   PubMed Web of Science ®Google Scholar
• John JP, Chengappa KNR, Baker RW, Gupta B, Mortimer MT. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995; 7: 119–25
   PubMedGoogle Scholar
• Frankenburg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994; 7: 129–32
   Google Scholar
• Michals ML, Crismon ML, Roberts S, Childs A. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 1993; 13: 198–203
   PubMed Web of Science ®Google Scholar
• McElroy SL, Dessain EC, Pope HG, Jr, Cole JO, Keck PE, Jr, Frankenburg FR, et al. Clozapine in the treatment of psychotic mood, disorders, schizoaffective, disorder, and, schizophrenia. J Clin, Psychiatry 1991; 52: 411–4
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402–5
   PubMed Web of Science ®Google Scholar
• Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39: 1219–21
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change. Biol Psychiatry 1998; 43: 520–4
   PubMedGoogle Scholar
• Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry 1997; 58: 63–72, suppl 10
   PubMedGoogle Scholar
• Mesard L, Wrigley A, Gee S. The ordering of antipsychotic drugs for the treatment of psychotic patients in VA hospitals. Biometrics Division, Office of Controller, Veterans Administration Central Office, Washington, DC 1976
   Google Scholar
• Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992; 160: 54–9, suppl 17
   Web of Science ®Google Scholar
• Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 1994; 55: 44–9
   PubMed Web of Science ®Google Scholar
• Dickson R, Williams R, Dalby JT. Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation [Letter]. Can J Psychiatry 1994; 39: 184
   PubMed Web of Science ®Google Scholar
• Patel JK, Salzman C, Green AI, Tsuang MT. Chronic schizophrenia: response to, clozapinerisperidone, and paroxetine. Am J Psychiatry 1997; 154: 543–6
   PubMed Web of Science ®Google Scholar
• Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996; 57: 395–7
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Lasser RA, Wines JD, Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997; 58: 137–45
   PubMed Web of Science ®Google Scholar
• Solomon DA, Keitner GI, Ryan CE, Miller IW. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review. J Clin Psychopharmacol 1998; 18: 38–49
   PubMed Web of Science ®Google Scholar
• Johns CA, Thompson JW. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995; 21: 607–19
   PubMed Web of Science ®Google Scholar
• Goff DC, Brotman AW, Waites M, McCormick S. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492–4
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153: 1625–7
   PubMed Web of Science ®Google Scholar
• Cole JO. Are there significant differences between the phenothiazines in their effectiveness in the treatment of schizophrenia?. Biological treatment of mental illness, M Rinkel. Farrar, Straus & Giroux, New York 1966; 507–22
   Google Scholar
• Iran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18
   Google Scholar
• Schooler NR. Comments on article by Tran and, colleagues, “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders”, [Letter]. J Clin, Psychopharmacol 1998; 18: 174–5
   PubMed Web of Science ®Google Scholar
• Gheuens J, Grebb JA. Comments on article by Tran and, associates, “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders”, [Letter]. J Clin, Psychopharmacol 1998; 18: 176–7
   PubMedGoogle Scholar
• Tollefson GD, Tran PV. Reply [Letter]. J Clin Psychopharmacol 1998; 18: 175–6
   Google Scholar
• Tollefson GD, Tran PV. Reply [Letter]. J Clin Psychopharmacol 1998; 18: 177–8
   Google Scholar
• Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155: 499–504
   PubMed Web of Science ®Google Scholar
• Lebowitz BD, Rudorfer MV. Treatment research at the millennium: from efficacy to effectiveness. J Clin Psychopharmacol 1998; 18: 1
   Google Scholar
• Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull 1997; 23: 623–35
   PubMed Web of Science ®Google Scholar
• Dickson RA, Edwards A. Clozapine and fertility [Letter]. Am J Psychiatry 1997; 154: 582–3
   PubMed Web of Science ®Google Scholar
• Conley RR, Carpenter WT, Jr, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154: 1243–7
   PubMedGoogle Scholar